Results with novel FXI inhibitor in AF set the stage for phase 3 trials
Christian Ruff, MD
Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine
Andrew Bellinger, MD, PhD
Benefit of TTR-stabilizer starts as early as 3 months in transthyretin amyloid cardiomyopathy
Ahmad Masri, MD
Deepak Gupta, MD
Loading...
We’re glad to see you’re enjoying PACE-CME…but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.